大剂量免疫球蛋白在封闭抗体阴性反复自然流产孕妇中的临床研究

Clinical effect of high-dose immunoglobulin in the treatment of pregnant women with negative blocking antibody and recurrent spontaneous abortion

目的探讨大剂量免疫球蛋白治疗封闭抗体阴性反复自然流产孕妇患者的临床效果。方法选取封闭抗体阴性反复自然流产孕妇患者共116例,随机分为观察组以及对照组各58例。对照组给予黄体酮联合口服药物治疗,观察组患者在此基础上给予大剂量免疫球蛋白静脉注射治疗。统计两组患者治疗后妊娠成功率,对比患者治疗前后封闭抗体阳性检查结果,同时测定两组患者治疗过程中不良反应发生率。结果观察组患者妊娠成功率94.8%,对照组患者妊娠成功率65.5%,差异有统计学意义(P<0.05)。观察组患者治疗后封闭抗体检查结果呈阳性率89.7%,对照组患者治疗后封闭抗体检查结果呈阳性率51.7%,差异有统计学意义(P<0.05)。同时观察组治疗过程中不良反应发生率8.6%,对照组不良反应发生率8.6%,差异无统计学意义(P>0.05)。结论在传统治疗方法上使用大剂量免疫球蛋白静脉注射治疗封闭抗体阴性反复自然流产孕妇患者有着良好的临床效果,安全性高且能有效提升患者封闭抗体阳性率,值得临床推广。

Objective To explore the clinical effect of high-dose immunoglobulin in the treatment of pregnant women with negative blocking antibody and recurrent spontaneous abortion. Methods 116 pregnant women with negative blocking antibody and recurrent spontaneous abortion were randomly divided into observation group and control group, 58 cases in each group. The control group was treated with progesterone and oral drugs, the observation group was treated with high dose intravenous immunoglobulin based on the control group＇s therapy. For the two groups, the pregnancy success rates after treatment, blocking antibody positive rates before and after treatment, and adverse reaction rates during treatment were compared. Results The pregnancy success rate of the observation group was 94.8%, while that of the control group was 65.5%, the difference was statistically significant（P〈0.05）. After treatment, the positive blocking antibody rate of the observation group was 89.7%, while that of the control group was 51.7%, the difference was statistically significant（P〈0.05）. During treatment, the adverse reaction rate was 8.6%, while that of the control group was the same, there was no statistical significance（P〉0.05）. Conclusion High-dose intravenous immunoglobulin has an excellent clinical effect in the treatment of pregnant women with negative blocking antibody and recurrent spontaneous abortion, which is safe and can effectively raise positive blocking antibody rate. It is worthy of clinical promotion.